Daniel Pink

8.5k total citations
130 papers, 3.0k citations indexed

About

Daniel Pink is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Daniel Pink has authored 130 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Pulmonary and Respiratory Medicine, 67 papers in Oncology and 52 papers in Gastroenterology. Recurrent topics in Daniel Pink's work include Gastric Cancer Management and Outcomes (54 papers), Gastrointestinal Tumor Research and Treatment (52 papers) and Sarcoma Diagnosis and Treatment (49 papers). Daniel Pink is often cited by papers focused on Gastric Cancer Management and Outcomes (54 papers), Gastrointestinal Tumor Research and Treatment (52 papers) and Sarcoma Diagnosis and Treatment (49 papers). Daniel Pink collaborates with scholars based in Germany, United States and Austria. Daniel Pink's co-authors include Peter Reichardt, Peter Hohenberger, Eva Wardelmann, Peter Thuss‐Patience, Albrecht Kretzschmar, Bernd Dörken, Dimosthenis Andreou, Per‐Ulf Tunn, Mathias Werner and Sebastian Bauer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Daniel Pink

121 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Pink Germany	25	1.9k	1.2k	783	698	317	130	3.0k
Raul S. González United States	23	471 0.3×	176 0.2×	588 0.8×	992 1.4×	71 0.2×	132	2.4k
Andrew Hayes United Kingdom	35	2.9k 1.6×	183 0.2×	683 0.9×	2.3k 3.3×	1.0k 3.2×	127	4.8k
Lesley Murray United Kingdom	33	1.1k 0.6×	254 0.2×	175 0.2×	1.5k 2.2×	113 0.4×	94	5.4k
Philip H. Gordon Canada	33	536 0.3×	128 0.1×	1.8k 2.3×	1.1k 1.6×	468 1.5×	138	3.4k
James Mueller Germany	28	1.2k 0.6×	382 0.3×	1.1k 1.4×	750 1.1×	33 0.1×	50	2.4k
Jonathan Harris United States	33	3.3k 1.8×	290 0.3×	4.7k 6.0×	3.5k 5.0×	103 0.3×	158	10.3k
Andrew C. Gordon United States	27	559 0.3×	53 0.0×	772 1.0×	205 0.3×	66 0.2×	138	2.8k
Rosario Carrillo Spain	16	224 0.1×	98 0.1×	364 0.5×	343 0.5×	142 0.4×	48	1.8k
Françoise Collin France	28	2.9k 1.5×	167 0.1×	328 0.4×	1.8k 2.6×	763 2.4×	113	3.7k
Françesc Solé Spain	39	519 0.3×	60 0.1×	386 0.5×	1.4k 2.0×	438 1.4×	241	5.5k

Countries citing papers authored by Daniel Pink

Since Specialization

Citations

This map shows the geographic impact of Daniel Pink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Pink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Pink more than expected).

Fields of papers citing papers by Daniel Pink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Pink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Pink. The network helps show where Daniel Pink may publish in the future.

Co-authorship network of co-authors of Daniel Pink

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Pink. A scholar is included among the top collaborators of Daniel Pink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Pink. Daniel Pink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Falkenhorst, Johanna, Philipp Ivanyi, Rainer Hamacher, et al.. (2025). Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial). Clinical Cancer Research. 31(19). 4059–4069.

Atmaca, Akin, Alex Stein, Daniel Pink, et al.. (2025). 1857P Eftilagimod alpha (soluble LAG-3 protein) combined with first-line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC): Updates from INSIGHT-003 (IKF614). Annals of Oncology. 36. S1000–S1000.

Waldschmidt, Johannes M., Anke Heidemeier, Peter Raab, et al.. (2025). Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition. Frontiers in Oncology. 14. 1518775–1518775.

Pink, Daniel, et al.. (2024). How Do Quality of Life (QoL) and Symptom Burden Evolve in Inpatient Palliative Care (PC) Patients following One Week of Care in a Specialized Palliative Care Unit (PCU)? A Comparison of Two Groups, with One Receiving Specialized Outpatient Palliative Care Prior to Admission. Cancers. 16(8). 1612–1612. 1 indexed citations

Schöffski, Patrick, Robin L. Jones, Mark Agulnik, et al.. (2024). Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report. ESMO Open. 9(7). 103487–103487. 1 indexed citations

Thuss‐Patience, Peter, Eray Goekkurt, M. Stahl, et al.. (2024). Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma. JAMA Network Open. 7(1). e2352830–e2352830. 9 indexed citations

Singer, Susanne, Leopold Hentschel, Stephan Richter, et al.. (2023). Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study. Journal of Cancer Research and Clinical Oncology. 149(9). 6009–6021. 3 indexed citations

Lorenzen, Sylvie, Claudia Pauligk, Eray Goekkurt, et al.. (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer. 23(1). 561–561. 5 indexed citations

Oberacker, Eva, Stefanie Corradini, Franziska Eckert, et al.. (2023). Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. International Journal of Hyperthermia. 40(1). 2236337–2236337. 4 indexed citations

10.

Reichardt, Peter, Dimosthenis Andreou, Anne Flörcken, et al.. (2023). Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).. Journal of Clinical Oncology. 41(16_suppl). 11500–11500. 12 indexed citations

11.

Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. European Journal of Cancer. 165. 48–57. 26 indexed citations

12.

Büttner, Matthias, Susanne Singer, Leopold Hentschel, et al.. (2021). Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. Supportive Care in Cancer. 30(1). 187–196. 15 indexed citations

13.

Pauligk, Claudia, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, et al.. (2020). 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S908–S908. 6 indexed citations

14.

Tintelnot, Joseph, Eray Goekkurt, Mascha Binder, et al.. (2020). Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 20(1). 503–503. 24 indexed citations

15.

Grünwald, Viktor, Sebastian Bauer, Bárbara Hermes, et al.. (2019). A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. Journal of Clinical Oncology. 37(15_suppl). TPS11075–TPS11075. 3 indexed citations

16.

Joensuu, Heikki, Mikael Eriksson, Kirsten Sundby Hall, et al.. (2015). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology. 34(3). 244–250. 149 indexed citations

17.

Bauer, Sebastian, Thomas Mühlenberg, Florian Grabellus, et al.. (2014). Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer. 110(5). 1155–1162. 39 indexed citations

18.

Rathmann, Nils, Steffen J. Diehl, Dietmar Dinter, et al.. (2014). Radioembolization in Patients with Progressive Gastrointestinal Stromal Tumor Liver Metastases Undergoing Treatment with Tyrosine Kinase Inhibitors. Journal of Vascular and Interventional Radiology. 26(2). 231–238. 13 indexed citations

19.

Pink, Daniel, et al.. (2009). Activity of paclitaxel in radiation induced and other secondary angiosarcomas. Journal of Clinical Oncology. 27(15_suppl). 10578–10578. 2 indexed citations

20.

Pink, Daniel. (2006). A Whole New Mind: Why Right Brainers will Rule the Future. 428 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact